中国科学院上海药物研究所谭敏佳等多个研究团队合作揭示了人类肺腺癌的蛋白质组学特征。该研究于2020年7月9日发表于《细胞》。

Title: Integrative Proteomic Characterization of Human Lung Adenocarcinoma

Author: Jun-Yu Xu, Chunchao Zhang, Xiang Wang, Linhui Zhai, Yiming Ma, Yousheng Mao, Kun Qian, Changqing Sun, Zhiwei Liu, Shangwen Jiang, Minghui Wang, Lin Feng, Lei Zhao, Ping Liu, Bo Wang, Xin Zhao, Hui Xie, Xiaoyun Yang, Liyuan Zhao, Yafei Chang, Jingya Jia, Xijun Wang, Yimin Zhang, Yaru Wang, Yikun Yang, Zhixiang Wu, Longhai Yang, Bin Liu, Teng Zhao, Shengguo Ren, Aihua Sun, Yang Zhao, Wantao Ying, Fei Wang, Guangshun Wang, Yi Zhang, Shujun Cheng, Jun Qin, Xiaohong Qian, Yi Wang, Jing Li, Fuchu He, Ting Xiao, Minjia Tan

Issue&Volume: 2020/07/09

Abstract: Genomic studies of lung adenocarcinoma (LUAD) have advanced our understanding of the disease’s biology and accelerated targeted therapy. However, the proteomic characteristics of LUAD remain poorly understood. We carried out a comprehensive proteomics analysis of 103 cases of LUAD in Chinese patients. Integrative analysis of proteome, phosphoproteome, transcriptome, and whole-exome sequencing data revealed cancer-associated characteristics, such as tumor-associated protein variants, distinct proteomics features, and clinical outcomes in patients at an early stage or with EGFR and TP53 mutations. Proteome-based stratification of LUAD revealed three subtypes (S-I, S-II, and S-III) related to different clinical and molecular features. Further, we nominated potential drug targets and validated the plasma protein level of HSP 90β as a potential prognostic biomarker for LUAD in an independent cohort. Our integrative proteomics analysis enables a more comprehensive understanding of the molecular landscape of LUAD and offers an opportunity for more precise diagnosis and treatment.

DOI: 10.1016/j.cell.2020.05.043

Source: https://www.cell.com/cell/fulltext/S0092-8674(20)30676-0